Latest & greatest articles for breast cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on breast cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on breast cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for breast cancer

1881. Magnetic resonance imaging of the breast for preoperative evaluation in patients with localized breast cancer

Magnetic resonance imaging of the breast for preoperative evaluation in patients with localized breast cancer Magnetic resonance imaging of the breast for preoperative evaluation in patients with localized breast cancer Magnetic resonance imaging of the breast for preoperative evaluation in patients with localized breast cancer BlueCross Blue Shield Association Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality (...) of this assessment has been made for the HTA database. The BlueCross BlueShield Association Technology Evaluation Center website ( ) includes the most recent 3 years of TEC Assessments. To request older reports, please use the “contact us” feature on the website. Citation BlueCross Blue Shield Association. Magnetic resonance imaging of the breast for preoperative evaluation in patients with localized breast cancer. Chicago: BlueCross BlueShield Association (BCBS). TEC Assessment 19(08). 2004 Authors' objectives

Health Technology Assessment (HTA) Database.2004

1882. Breast MRI for management of patients with locally advanced breast cancer who are being referred for neoadjuvant chemotherapy

Breast MRI for management of patients with locally advanced breast cancer who are being referred for neoadjuvant chemotherapy Breast MRI for management of patients with locally advanced breast cancer who are being referred for neoadjuvant chemotherapy Breast MRI for management of patients with locally advanced breast cancer who are being referred for neoadjuvant chemotherapy BlueCross BlueShield Association Record Status This is a bibliographic record of a published health technology assessment (...) . No evaluation of the quality of this assessment has been made for the HTA database. The BlueCross BlueShield Association Technology Evaluation Center website ( ) includes the most recent 3 years of TEC Assessments. To request older reports, please use the “contact us” feature on the website. Citation BlueCross BlueShield Association. Breast MRI for management of patients with locally advanced breast cancer who are being referred for neoadjuvant chemotherapy. Chicago: BlueCross BlueShield Association (BCBS

Health Technology Assessment (HTA) Database.2004

1883. Follow-up care of patients treated for breast cancer: a structured review

Follow-up care of patients treated for breast cancer: a structured review Follow-up care of patients treated for breast cancer: a structured review Follow-up care of patients treated for breast cancer: a structured review Collins R F, Bekker H L, Dodwell D J CRD summary This review assessed the effectiveness of breast cancer follow-up services. The authors' conclusions appear appropriately cautious, however, the poor quality of the majority of the included studies and the poor reporting (...) of review methodology mean that their reliability cannot be accurately determined. Authors' objectives To assess the effectiveness of follow-up services for breast cancer patients. Searching MEDLINE, EMBASE, CINAHL, British Nursing Index, RCN Journals Database, PsycINFO, National Research Register, HMIC, the Cochrane Database of Systematic Reviews, and the NHS Centre for Reviews and Dissemination's databases were searched from 1989 to April 2001 for publications written in English. In addition

DARE.2004

1884. Systematic review of taxane-containing versus non-taxane-containing regimens for adjuvant and neoadjuvant treatment of early breast cancer

Systematic review of taxane-containing versus non-taxane-containing regimens for adjuvant and neoadjuvant treatment of early breast cancer Systematic review of taxane-containing versus non-taxane-containing regimens for adjuvant and neoadjuvant treatment of early breast cancer Systematic review of taxane-containing versus non-taxane-containing regimens for adjuvant and neoadjuvant treatment of early breast cancer Nowak A K, Wilcken N R, Stockler M R, Hamilton A, Ghersi D CRD summary This review (...) assessed the effect of taxanes on response and survival in women with early breast cancer. Ten randomised controlled trials with 12,159 women found that adjuvant taxanes may improve survival. The effect of neoadjuvant taxanes remains uncertain. This review may need early updating as the authors identified 19 other unpublished trials available in abstract form or not yet complete. Authors' objectives To assess the effect of taxanes on response and survival in women with early breast cancer. Searching

DARE.2004

1885. The treatment of lymphedema related to breast cancer: a systematic review and evidence summary

The treatment of lymphedema related to breast cancer: a systematic review and evidence summary The treatment of lymphedema related to breast cancer: a systematic review and evidence summary The treatment of lymphedema related to breast cancer: a systematic review and evidence summary Kligman L, Wong R K, Johnston M, Laetsch N S CRD summary The review assessed physical and medical therapy interventions for women with lymphoedema after breast cancer treatment. Whilst some evidence was found (...) to support the use of compression therapy, the authors' conclusion that further studies are needed appears appropriate. However, relevant foreign language and unpublished studies might have been missed. Authors' objectives To provide an evidence summary of the treatment options for women with lymphoedema following treatment for breast cancer. Searching MEDLINE, Cancerlit, HealthSTAR, CINAHL and PREMEDLINE were searched from May 2000 to March 2002; the search terms were reported. The Cochrane Library

DARE.2004

1886. HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis

HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis Elkin E B, Weinstein K C, Winer E P, Kuntz K M, Schnitt S J, Weeks J C Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract (...) contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The identification of patients with metastatic breast cancer, whose tumours exhibited human epidermal growth factor receptor-2 protein (HER-2) overexpression or gene amplification, and their subsequent treatment with trastuzumab was examined. HER-2 was identified by either an immunohistochemical assay (IHC) kit

NHS Economic Evaluation Database.2004

1887. Tamoxifen for breast cancer prevention: a framework for clinical decisions

Tamoxifen for breast cancer prevention: a framework for clinical decisions Tamoxifen for breast cancer prevention: a framework for clinical decisions Tamoxifen for breast cancer prevention: a framework for clinical decisions Cykert S, Phifer N, Hansen C Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment (...) on the reliability of the study and the conclusions drawn. Health technology The use of tamoxifen (20 mg/day), taken for 5 years, as chemoprevention for women at risk of breast cancer. Type of intervention Primary prevention. Economic study type Cost-utility analysis. Study population The model analysed data for a hypothetical cohort of women aged 50 years, with an estimated 5-year breast cancer risk of 3.4%, who had an intact uterus. This represented the average patient in the Breast Cancer Prevention Trial

NHS Economic Evaluation Database.2004

1888. Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer

Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor (...) -positive breast cancer Hillner B E Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of anastrozole (1 mg) as initial adjuvant therapy for women with early-stage estrogen receptor-positive breast cancer. Type of intervention

NHS Economic Evaluation Database.2004

1889. Simulation modeling of change to breast cancer detection age eligibility recommendations in Ontario, 2002 - 2021

Simulation modeling of change to breast cancer detection age eligibility recommendations in Ontario, 2002 - 2021 Simulation modeling of change to breast cancer detection age eligibility recommendations in Ontario, 2002 - 2021 Simulation modeling of change to breast cancer detection age eligibility recommendations in Ontario, 2002 - 2021 Hunter D J, Drake S M, Shortt S E, Dorland J L, Tran N Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion (...) on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology A change in the eligibility requirements for breast cancer screening was examined. This change was the inclusion of women aged between 40 and 49 years, in addition to previous recommendations for women over the age of 50 years. Type of intervention Screening. Economic study type Cost

NHS Economic Evaluation Database.2004

1890. Paclitaxel and epirubicin versus paclitaxel and carboplatin as first-line chemotherapy in patients with advanced breast cancer: a phase III study conducted by the Hellenic Cooperative Oncology Group

Paclitaxel and epirubicin versus paclitaxel and carboplatin as first-line chemotherapy in patients with advanced breast cancer: a phase III study conducted by the Hellenic Cooperative Oncology Group Paclitaxel and epirubicin versus paclitaxel and carboplatin as first-line chemotherapy in patients with advanced breast cancer: a phase III study conducted by the Hellenic Cooperative Oncology Group Paclitaxel and epirubicin versus paclitaxel and carboplatin as first-line chemotherapy in patients (...) with advanced breast cancer: a phase III study conducted by the Hellenic Cooperative Oncology Group Fountzilas G, Kalofonos H P, Dafni U, Papadimitriou C, Bafaloukos D, Papakostas P, Kalogera-Fountzila A, Gogas H, Aravantinos G, Moulopoulos L A, Economopoulos T, Pectasides D, Maniadakis N, Siafaka V, Briasoulis E, Christodoulou C, Tsavdaridis D, Makrantonakis P, Razis E, Kosmidis P, Skarlos D, Dimopoulos M A Record Status This is a critical abstract of an economic evaluation that meets the criteria

NHS Economic Evaluation Database.2004

1891. Benefits and costs of interventions to improve breast cancer outcomes in African American women

Benefits and costs of interventions to improve breast cancer outcomes in African American women Benefits and costs of interventions to improve breast cancer outcomes in African American women Benefits and costs of interventions to improve breast cancer outcomes in African American women Mandelblatt J S, Schechter C B, Yabroff K R, Lawrence W, Dignam J, Muennig P, Chavez Y, Cullen J, Fahs M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion (...) on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Interventions for breast cancer control, such as screening (patient reminders or lay health workers) and optimal treatment (consistent with current recommendations), were examined. Type of intervention Screening and treatment. Economic study type Cost-effectiveness analysis. Study

NHS Economic Evaluation Database.2004

1892. Evaluation of breast cancer risk assessment techniques: a cost-effectiveness analysis

Evaluation of breast cancer risk assessment techniques: a cost-effectiveness analysis Evaluation of breast cancer risk assessment techniques: a cost-effectiveness analysis Evaluation of breast cancer risk assessment techniques: a cost-effectiveness analysis Ozanne E M, Esserman L J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed (...) by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The following four strategies for the prevention of breast cancer (BC) in high-risk women were examined. Screening: routine screening with mammography for all women. Tamoxifen: tamoxifen therapy for all women. Ductal lavage (DL): an attempt of DL for all women, with tamoxifen used only by women with atypia. Random fine-needle aspiration (rFNA): rFNA for all women, with tamoxifen used only by women

NHS Economic Evaluation Database.2004

1893. Clinical practice guidelines for the management of breast cancer in younger women

Clinical practice guidelines for the management of breast cancer in younger women Cancer Australia | A national government agency working to reduce the impact of cancer on all Australians ") //--> ") //--> Search form Search News Featured Sites Featured Video Visit our channel Video of Introduction to the Statement View the video transcript ( ) Cancer types A - Z list of cancer types In Focus Copyright © 2017 - Cancer Australia

National Breast and Ovarian Cancer Centre2004

1894. Early detection of breast cancer

Early detection of breast cancer Cancer Australia | A national government agency working to reduce the impact of cancer on all Australians ") //--> ") //--> Search form Search News Featured Sites Featured Video Visit our channel Video of Introduction to the Statement View the video transcript ( ) Cancer types A - Z list of cancer types In Focus Copyright © 2017 - Cancer Australia

National Breast and Ovarian Cancer Centre2004

1896. MRI screening for breast cancer in genetically high-risk women

MRI screening for breast cancer in genetically high-risk women MRI screening for breast cancer in genetically high-risk women MRI screening for breast cancer in genetically high-risk women Mundy L, Merlin T, Braunack-Mayer A, Hiller J E Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Mundy L, Merlin T, Braunack-Mayer A, Hiller J E. MRI (...) screening for breast cancer in genetically high-risk women. Adelaide: Adelaide Health Technology Assessment (AHTA). 2004 Authors' conclusions The current “gold standard” for breast cancer screening in Australia is mammography, which is offered free to all Australian women 40 years and over, by BreastScreen Australia. Mammography involves exposing the patient to radiation, which may represent a risk in women with a genetic pre-disposition to breast cancer. On a mammogram of normal breast tissue, fat

Health Technology Assessment (HTA) Database.2004

1897. Tridimensional radiotherapy for breast cancer

Tridimensional radiotherapy for breast cancer Tridimensional radiotherapy for breast cancer Tridimensional radiotherapy for breast cancer Pichon Riviere A, Augustovski F, Cernadas C, Ferrante D, Regueiro A, Garcia Marti S Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Pichon Riviere A, Augustovski F, Cernadas C, Ferrante D, Regueiro (...) A, Garcia Marti S. Tridimensional radiotherapy for breast cancer. Ciudad de Buenos Aires: Institute for Clinical Effectiveness and Health Policy (IECS) 2004 Authors' objectives The aim of this report is to evaluate tridimensional radiotherapy for breast cancer Authors' conclusions It is important to point out that the scientific evidence that suggests that both tridimensional conformal radiotherapy and IMRT can be of benefit to minimize normal tissue structure involvement and to contribute to a lower

Health Technology Assessment (HTA) Database.2004

1898. Capecitabine in breast cancer

Capecitabine in breast cancer Capecitabine in breast cancer Capecitabine in breast cancer Pichon Riviere A, Augustovski F, Cernadas C, Ferrante D, Regueiro A, Garcia Marti S Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Pichon Riviere A, Augustovski F, Cernadas C, Ferrante D, Regueiro A, Garcia Marti S. Capecitabine in breast cancer (...) . Ciudad de Buenos Aires: Institute for Clinical Effectiveness and Health Policy (IECS) 2004 Authors' objectives This report aims to assess the effectiveness of capecitabine in breast cancer. Authors' conclusions Capecitabine in combination with docetaxel can be a therapeutic alternative when ALL the following criteria are met: 1.Patients with locally advanced or metastatic breast cancer. 2.Patients failed or are not elegible for antracycline containing regimens. It must be taken into account that, up

Health Technology Assessment (HTA) Database.2004

1899. Diagnostic accuracy and clinical usefulness of Positron Emission Tomography (PET) in breast and ovarian cancer recurrence (HTA report)

Diagnostic accuracy and clinical usefulness of Positron Emission Tomography (PET) in breast and ovarian cancer recurrence (HTA report) Eficacia diagnostica y utilidad clinica de la tomografia por emision de positrones (PET) en la recurrencia de cancer de mama y ovario [Diagnostic accuracy and clinical usefulness of Positron Emission Tomography (PET) in breast and ovarian cancer recurrence] Eficacia diagnostica y utilidad clinica de la tomografia por emision de positrones (PET) en la recurrencia (...) de cancer de mama y ovario [Diagnostic accuracy and clinical usefulness of Positron Emission Tomography (PET) in breast and ovarian cancer recurrence] Lema L V, Garcia-Caeiro A Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Lema L V, Garcia-Caeiro A. Eficacia diagnostica y utilidad clinica de la tomografia por emision de positrones (PET

Health Technology Assessment (HTA) Database.2004